Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients

Acta Neurologica Scandinavica

Volumn 97, Issue 6, 1998, Pages 359-365

  Wandinger, K P ^a   Wessel, K ^a   Trillenberg, P ^a   Heindl, N ^a   Kirchner, H ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Cytokines; Immunoglobulins; Interleukin 1; Macrophage activation; Methylprednisolone; Multiple sclerosis; NK cells

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1; INTERLEUKIN 2; METHYLPREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE TYPING; MALE; MULTIPLE SCLEROSIS; T LYMPHOCYTE SUBPOPULATION;

EID: 0031831134     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1998.tb05966.x     Document Type: Article

References (63)

1. FFRENCH-CONSTANT C. Pathogenesis of multiple sclerosis. Lancet 1994: 343: 271-5.
2. LUBLIN FD, REINGOLD SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996: 46: 907-11.
3. BECK J, RONDOT P, CATINOT L, FALCOFF L, KIRCHNER H. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand 1988: 78: 318-23.
4. IMAMURA K, SUZUMURA A, HAYASHI F, MARUNOUCHI T. Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. Acta Neurol Scand 1993: 87: 281-5.
5. RIECKMANN P, ALBRECHT M, KITZE B et al. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 1995: 37: 82-8.
6. GRIFFITHS TD, NEWMAN PK. Steroids in multiple sclerosis. J Clin Pharm Ther 1994: 19: 219-22.
7. BECK RW, CLEARY PA, TROBE JD et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993: 329: 1764-9.
8. ROUJEAU JC. Pulse glucocorticoid therapy. The "big shot" revisited. Arch Dcrmatol 1996: 132: 1499-502.
9. DEFER GL, BARRE J, LEDUDAL P, TILLEMENT JP, DECOS JD. Methylprednisolone infusion during acute exacerbation of MS: plasma and CSF concentrations. Eur Neurol 1995: 35: 143-8.
10. MEIER AC. Mechanisms of immunosuppression by glucocorticoids. Eur J Endocrinol 1996: 134: 50.
11. CROCKARD AD, TREACY MT, DROOGAN AG, HAWKINS SA. CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and γ-interferon production during intravenous methylprednisolone treatment of multiple sclerosis. J Neurol 1996: 243: 475-81.
12. BOUMPAS DT, ANASTASSIOU ED, OLDER SA, TSOKOS GC, NELSON DL, BALOW JE. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest 1991: 87: 1739-47.
13. SNIJDEWINT FGM, KAPSENBURG ML, WAUBEN-PENRIS PJJ, BOS JD. Corticosteroids class-dependently inhibit in vitro Th1- and Th2-type cytokine production. Immunopharmacol 1995: 29: 93-101.
14. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M. Immunosuppression of NF-κB activity through induction of IκB synthesis. Science 1995: 270: 286-90.
15. AYANLAR-BATUMAN O, FERRERO AP, DIAZ A, JIMENSEZ SA. Regulation of transforming growth factor-beta 1 gene expression by glucocorticoids in normal human T lymphocytes. J Clin Invest 1991: 88: 1574-80.
16. BECK J, RONDOT P, JULLIEN P, WIETZERBIEN J, LAWRENCE DA. TGF-ß-like activity produced during regression of exacerbations in multiple sclerosis. Acta Neurol Scand 1991: 84: 452-5.
17. RIECKMANN P, ALBRECHT M, KITZE B et al. Cytokine mRNA levels in mononuclear blood cells from patients with multiple sclerosis. Neurology 1994: 44: 1523-6.
18. KERMODE AG, THOMPSON AJ, MACMANUS DG et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis: pathogenetic and clinical implications. Brain 1990: 113: 1477-89.
19. GASPERINI C, POZZILLI C, BASTIANELLO S et al. The influence of clinical relapse and steroid therapy on the development of Gd-enhancing lesions - A longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurol Scand 1997: 95: 201-7.
20. CRONSTEIN BN, KIMMEL SC, LEVIN RI, MARTINUIUK F, WEISSMANN G. A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1992: 89: 9991-5.
21. LEPPERT D, WAUBANT E, GALARDY R, BUNNETT NW, HAUSER SL. T-cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995: 154: 4379-89.
22. ROSENBERG GA, DENCOFF JE, CORREA N, REINERS M, FORD CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996: 46: 1626-32.
23. MAEDA A, SOBEL RA. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996: 55: 300-9.
24. ZETTL UK, GOLD R, TOYKA KV, HARTUNG HP. Intravenous glucocorticosteroid treatment augments apoptosis of inflammatory T cells in experimental autoimmune neuritis (EAN) of the lewis rat. J Neuropathol Exp Neurol 1995: 54: 540-7.
25. BLACKWELL GJ, CARNUCCIO R, DIROSA M, FLOWER RJ, PARENTE L, PERSICO P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 1980: 287: 147.
26. 2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 1980: 77: 2533-6.
27. REDER AT, THAPAR M, SAPUGAY AM, JENSEN MA. Prostaglandins and inhibitors of arachidonate metabolism suppress experimental allergic encephalomyelitis. J Neuroimmunol 1994: 54: 117-27.
28. KIRCHNER H, KLEINICKE C, DIGEL W. A whole-blood technique for testing production of human interferon by leukocytes. J Immunol Meth 1982: 48: 213-19.
29. POSER CM, PATY DW, SCHEINBERG L et al. New diagnostic criteria for multiple sclerosis; guidelines for research protocols. Ann Neurol 1983: 13: 227-31.
30. KURTZKE JF. Rating neurologic impairment in multiple sclerosis; an expanded disability status scale (EDSS). Neurology 1983: 33: 1444-52.
31. DINARELLO CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991: 77: 1627-52.
32. HSI ED, REMICK DG. Monocytes are the major producers of interleukin-1ß in an ex vivo model of local cytokine production. J Interferon Cytokine Res 1995: 15: 89-94.
33. MCCARRON RM, WANG L, RACKE MK, MCFARLIN DE, SPATZ M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 1993: 43: 23-30.
34. MARTIN R, MCFARLAND HF. Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis. Crit Rev Clin Lab Sci 1995: 32: 121-82.
35. DAYTON ET, MAJOR EO. Recombinant human interleukin 1-beta induces production of prostaglandins in primary human fetal astrocytes and immortalized human fetal astrocyte cultures. J Neuroimmunol 1996: 71: 11-18.
36. CHOFFLON M, JUILLARD C, JUILLARD P, GAUTHIER G, GRAU GE. Tumor necrosis factor α production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992: 3: 523-31.
37. GIOVANNONI G, LAI M, KIDD D et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997: 120: 1-13.
38. MAIMONE D, REDER AT, GREGORY S. T-cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis. Cell Immunol 1993: 146: 96-106.
39. SNYDER DS, UNANUE ER. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. J Immunol 1982: 129: 1803-5.
40. NEIFELD JP, LIPPMAN ME, TORMEY DC. Steroid hormone receptors in normal human lymphocytes. Induction of glucocorticoid receptor activity by phytohemagglutinin stimulation. J Biol Chem 1977: 252: 2972-7.
41. SMITH KA, CRABTREE GR, KENNEDY SJ, MUNCK AU. Glucocorticosteroid receptors and sensitivity of mitogen stimulated and unstimulated lymphocytes. Nature 1977: 267: 523-5.
42. FENTON MJ, CLARK BD, COLLINS KL, WEBB AC, RICH A, AURON PE. Transcriptional regulation of the human prointerleukin 1ß gene. J Immunol 1987: 138: 3972-9.
43. KNUSDEN PJ, DINARELLO CA, STROM TB. Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin-1 in U 937 cells. J Immunol 1987: 139: 4129-34.
44. SCHEINMAN RI, COGSWELL PC, LOFQUIST AK, BALDWIN AS. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 1995: 270: 283-6.
45. LEE SW, TSOU AP, CHAN H et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1ß gene and decrease the stability of interleukin 1ß mRNA. Proc Natl Acad Sci USA 1988: 85: 1204-8.
46. VACCA A, MARTINOTTI S, SCREPANTI I et al. Transcriptional regulation of the interleukin 2 gene by glucocorticoid hormones. Role of steroid receptor and antigen-responsive 5′-flanking sequences. J Biol Chem 1990: 265: 8075-80.
47. GEARING AJH, BECKETT P, CHRISTODOULOU M et al.Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994: 370: 555-7.
48. SHARIEF MK, HENTGES R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991: 325: 467-72.
49. WANDINGER KP, WESSEL K, NEUSTOCK P, SIEKHAUS A, KIRCHNER H. Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. J Neurol Sci 1997: 149: 87-93.
50. ATHENS JW, HAAB OP, RAAB SO et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 1961: 40: 989-95.
51. MONTGOMERY KF, OSBORN L, HESSION C et al. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci USA 1991: 88: 6523-7.
52. SPRINGER TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994: 76: 301-14.
53. CANNELLA B, RAINE CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol 1995: 37: 424-35.
54. CALABRESI PA, TRANQUILL LR, DAMBROSIA JM et al. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol 1997: 41: 669-74.
55. GIOVANNONI G, LAI M, THORPE J et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis-correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997: 48: 1557-65.
56. HARTUNG HP, REINERS K, ARCHELOS JJ et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995: 38: 186-93.
57. BEVILACQUA MP. Endothelial-leukocyte adhesion molecules. Annu Rev Immunol 1993: 11: 767-804.
58. MILLER DH, THOMPSON AJ, MORRISSEY SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for possible mechanisms of therapeutic effect. J Neurol Neurosurg Psychiatry 1992: 55: 450-3.
59. BLOEMENA E, WEINREICH S, SCHELLEKENS PT. The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo. Clin Exp Immunol 1990: 80: 460-6.
60. GALLO P, CHIUSOLE M, SANZARI M et al. Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients. Acta Neurol Scand 1994: 89: 95-101.
61. SALMAGGI A, BALDETORP B, MILANESE C, NESPOLO A, PARMA R, SANDBERG-WOLLHEIM M. Analysis of peripheral blood lymphocyte phenotype and function during dexamethazone treatment of progressive multiple sclerosis. Acta Neurol Scand 1991: 84: 91-7.
62. GLASSER L, HICKS MJ, LINDBERG RE, JONES JF. The effect of in vivo dexamethazone on lymphocyte subpopulations: differential response of EAhu rosette-forming cells. Clin Immunol Immunopathol 1981, 18: 22-31.
63. PITZALIS C, SHARRACK B, GRAY IA, LEE A, HUGHES RAC. Comparison of the effect of oral versus intravenous methylprednisolone regimens on peripheral blood T-lymphocyte adhesion molecule expression, T-cell subsets distribution and TNF alpha concentrations in multiple sclerosis. J Neuroimmunol 1997: 74: 62-8.